Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $285.84 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Bio-Techne Stock Down 2.0 %

Bio-Techne stock opened at $72.05 on Tuesday. The firm has a market capitalization of $11.45 billion, a P/E ratio of 76.65, a P/E/G ratio of 5.42 and a beta of 1.27. The stock’s fifty day simple moving average is $74.67 and its 200-day simple moving average is $74.38. Bio-Techne has a twelve month low of $61.16 and a twelve month high of $85.57. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14.

Insider Buying and Selling

In other news, CEO Kim Kelderman sold 13,392 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the sale, the chief executive officer now owns 39,004 shares in the company, valued at approximately $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TECH shares. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Scotiabank raised their price objective on shares of Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a report on Thursday, October 31st. Finally, Robert W. Baird boosted their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Bio-Techne presently has an average rating of “Moderate Buy” and a consensus price target of $84.00.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.